Apogee Therapeutics, Inc. 8-K

What Happened
Apogee Therapeutics, Inc. filed an 8-K on April 24, 2026 (Item 5.02) reporting that directors Andrew Gottesdiener, M.D., and Peter Harwin notified the Board on April 21, 2026 of their intent to resign, with both resignations effective May 11, 2026. The filing states the departures are not the result of any disagreement with the company on matters relating to its operations, policies or practices. The Board will be reduced from nine directors to seven effective May 11, 2026. The report was signed by CEO Michael Henderson, M.D.

Key Details

• Filing: Form 8-K, Item 5.02 (Departure of Directors or Certain Officers), filed April 24, 2026.
• Directors resigning: Andrew Gottesdiener, M.D., and Peter Harwin.
• Notice given: April 21, 2026; effective date: May 11, 2026.
• Board size change: reduced from nine to seven directors; resignations reportedly not due to any disagreement with the company.

Why It Matters
This is a governance change investors should note: two board departures reduce board membership and could affect committee composition, oversight, and voting dynamics until replacements (if any) are named. The company did not report disputes or operational issues tied to the resignations. Investors should watch for subsequent filings (additional 8-Ks or proxy statements) announcing any director appointments or committee reassignments.